Articles tagged with Cancer Medication
A study by Hokkaido University scientists found that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer. High levels of IL-34 were associated with poor prognosis in TNBC patients.
A new mechanism for anticancer drug resistance has been discovered in gastric cancer, involving a molecule called Annexin A6. The molecule is secreted by cancer-associated fibroblasts and taken up by gastric cancer cells, leading to increased resistance to treatment.
Scientists at Princess Margaret Cancer Centre discover a promising approach to identify the best patients for targeted therapy in triple negative breast cancer. Using patient-derived cell lines, researchers found a correlation between levels of RB1 protein and decreased growth in cancer cells.
A new study discovered that GULP1 is a key regulator of the NRF2-KEAP1 signaling axis in urothelial carcinoma. GULP1 knockdown led to increased tumor growth and resistance to cisplatin treatment.
Scientists at Scripps Research have discovered a molecule that can activate the STING protein to help patients fight cancer. The optimized STING-activator, SR-717, dramatically suppressed tumor growth and boosted immune cells in an animal model of aggressive melanoma.
Adult cancer survivors are more likely to misuse prescription opioids compared to those without cancer. The study found a significant association between cancer diagnosis and increased opioid misuse.
A new study from Lund University found that PDE5 inhibitors can improve prognosis in patients with colorectal cancer. The study revealed a 18% lower risk of death and reduced metastases among men who used the drugs after diagnosis.
The COVID-19 pandemic worsens existing health disparities in cancer patients, with marginalized communities facing poorer treatment outcomes. Healthcare providers must acknowledge these disparities to deliver equitable care.
Recent advances in treatment have led to a sharp reduction in lung cancer mortality rates in the US, with non-small cell lung cancer deaths decreasing faster than incidence. The study found significant improvements in survival for both men and women, particularly after the introduction of targeted therapies.
A McGill-led study unlocks the behavior of an enzyme involved in cancer cell spread, revealing a delicate interaction between PRL3 and magnesium transport proteins crucial to colorectal cancer growth. This finding calls into question long-standing hypotheses about PRL3's role in cancer spread.
A new study aims to investigate how chemotherapy affects children's brain development and cognitive function, particularly sensory processing, memory, and attention. The researchers hope to develop protective interventions to prevent permanent harm from 'chemo brain'.
Researchers successfully reduced metastatic spread by using medication treatment around the time of surgery, preventing development of metastases. The study found a significant reduction in metastasis development rate in treated patients compared to those receiving a placebo.
A new study uses patient-specific tumor organoids to identify the most effective chemotherapy protocol for treating advanced stages of colon and appendiceal cancer. The approach shows promise in tailoring treatment to individual patients, potentially increasing life expectancy.
Researchers efficiently synthesized cepafungin I, a natural compound with promise as an anti-cancer agent, using a lean new process that overcame its complex molecular structure. The compound targets the proteasome, a strategy used by many existing cancer medications.
A new study by Vanderbilt University Medical Center researchers finds that Medicare Part D plans favor generic drugs over brand-name counterparts, with only 0.9% of plans covering only the brand name in 2019. Generic drugs were often on the same or lower cost-sharing tier as brand names, saving patients out-of-pocket costs.
Researchers at GW Cancer Center demonstrate that HDAC6 inhibitors can both enhance immunotherapy's effectiveness and decrease breast cancer's invasiveness, offering new treatment options for triple-negative breast cancer patients.
Disulfiram, used to treat alcoholism, has shown potential against SARS-CoV-2 by inhibiting viral replication and reducing glutathione levels, while neratinib, an experimental breast cancer treatment, also demonstrates effectiveness in blocking coronavirus protease M pro.
Researchers at Ohio State University Comprehensive Cancer Center have found that molecular characteristics can refine prognostic recommendations for AML patients under age 60. The study detected mutations in several categories, which were associated with better or worse outcomes and may help improve treatment choices.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a novel drug target, PPP1R1B, that stops the spread of pancreatic cancer in mice. Increased levels of this protein have been found in tumor samples from people with metastatic pancreatic cancer, suggesting it has therapeutic potential.
Researchers at Huntsman Cancer Institute develop new models to study molecular characteristics of lung and pancreas tumors driven by NTRK1 mutations. The findings aim to identify effective treatments for patients with NTRK1-driven cancers, which have proven resistant to current therapies.
Researchers studying cichlid fishes aim to understand genetic mechanisms controlling facial development, which may also apply to humans. The study's findings could help determine if certain medications prescribed for human diseases might cause facial malformations in unborn babies.
A blood test can predict which cancer patients will benefit from immunotherapy, a treatment option for advanced cancers. The test analyzes changing levels of tumour fragments in the blood to identify those who will respond well to the treatment.
Researchers at CeMM developed a scalable strategy to discover novel molecular glue degraders, which can eliminate disease-causing proteins by targeting the cellular protein quality control system. The study identifies a set of novel compounds that induce the degradation of cyclin K, essential in many cancer types.
A new study from UC San Diego researchers reveals that an investigational drug candidate called tipifarnib shows promise in treating head and neck cancer tumors with mutations in the HRAS gene. The findings support the idea that HRAS represents a druggable oncogene in HNSCC, providing a precision therapeutic option.
Dr. Britta Will, an assistant professor at Albert Einstein College of Medicine, has won the prestigious Pershing Square Sohn Prize for her innovative cancer research. Her studies focus on understanding mechanisms that create and sustain cancer stem cells in acute myeloid leukemia and myelodysplastic syndrome.
Researchers found that combining pan-Bcl-2 inhibitors with cancer treatments can cause healthy cells to die, leading to reproductive and developmental defects. The study highlights the need for awareness about adverse effects of certain drugs like navitoclax.
Researchers identified phosphoprotein biomarkers to guide cancer therapy, demonstrating a novel approach for identifying and detecting tumor drivers. The study's findings suggest that precision medicine is a realizable goal for rare and recalcitrant cancers.
A deep learning algorithm can quickly and accurately screen cancer patient biopsies for genetic alterations that inform treatment options and likelihood to respond to specific therapies. The study found detectable mutations in 13 out of 14 tested tumor types, including lung, colorectal, breast, and gastric cancers.
Researchers found that patients treated with radioactive iodine and surgery for hyperthyroidism have a higher risk of dying from solid cancer compared to those treated with anti-thyroid drugs. The study suggests that the long-term effects of these treatments on cancer mortality rates are significant.
Physician-scientists use a comprehensive genomic analysis tool to determine the best treatment plan for each individual patient. The study suggests that mutations in the TERT gene can predict a patient's response to immune checkpoint inhibitors.
Newly released CCC19 data show a racial disparity in access to Remdesivir, an antiviral drug that shortens hospital stays, and increased mortality associated with dexamethasone, a steroid. Black patients were half as likely to receive Remdesivir as white patients.
Researchers found that some mutations actually generate 'noise' that can counteract cancer development, leading to a dead end. New drug combinations aim to reactivate suppressed pathways to disrupt oncogenic signal transduction in cancer cells.
Researchers have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children. The drug made tumor cells more sensitive to radiation therapy and proved capable of killing tumor cells and preventing new colony formation.
Scientists have tracked quadruple helix DNA formation in living human cells for the first time, allowing them to see how it works and its possible role in cancer. The discovery could reveal new targets for drugs that interrupt gene expression, a fundamental process in gene regulation.
Scientists have discovered a potential new target for treating Ewing sarcoma, a childhood cancer that affects the bone and soft tissue. The researchers found that an imbalance in genetic code-reading machines causes nucleoli to break up into smaller entities in Ewing sarcoma.
Researchers discovered that a protein called Neuropilin-1 (NRP1) suppresses immune responses to cancer. Blocking NRP1 improves the immune system's ability to remember tumors, leading to better protection against recurrence and improved response to immunotherapy.
Researchers at Uppsala University have discovered new ways to combine drugs for glioblastoma patients, tailoring therapy to individual tumours. The study characterised how genetic aberrations influence drug effectiveness, revealing two main subgroups based on response and mutations.
Moffitt researchers found that umbralisib, a PI3K/CK1ε inhibitor, showed fewer immune-mediated side effects compared to traditional PI3K inhibitors. The study suggests that dual inhibition may improve safety profiles for CLL patients.
Researchers found that arsenic trioxide can restore the body's natural antiviral factories to fight adenovirus infections. The medication has been approved for leukemia treatment and shows promise in inhibiting adenovirus replication without developing resistance.
Peter S. Conti, MD, PhD, received the 2020 Benedict Cassen Prize for his pioneering work in radiopharmaceuticals and clinical PET applications for cancer imaging. The award recognizes his contributions to advancing nuclear medicine and molecular imaging.
A study by TGen has identified a drug, SP-2577, which can enable the immune system to attack ovarian cancer. The drug, also known as Seclidemstat, was developed to inhibit LSD1, a protein that is abundant in SCCOHT ovarian cancer.
A ground-breaking clinical trial is underway at Sheba Medical Center in Israel to evaluate the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor. The trial aims to treat resistant metastatic melanoma, triple-negative breast cancer, renal cell carcinoma, and non-sm...
A recent study analyzing 10 years of HPV-vaccine related Facebook posts reveals that anti-vaxxers have gained a stronger voice against the use of the human papillomavirus vaccine. Negative posts displayed a 45% increase in public engagement, with some showing negative views on vaccine safety and effectiveness.
A large study found that taking common hypertension medications such as ACE inhibitors and ARBs can lower the risk of developing colorectal cancer. The benefits were seen in patients over 55 and those with a history of colon polyps, but only for the first three years after a negative baseline colonoscopy.
A study published in CANCER found that Medicaid expansion significantly reduced the likelihood of being diagnosed with deadly metastatic cancer among Americans with low income. The research analyzed data from 12,760 individuals and showed a 15% lower odds of having metastatic cancer after Medicaid expansion.
Brooke Emerling receives a four-year grant to study targeting tumors with p53 gene mutations, which are present in most human cancers. Her research aims to develop new approaches to eliminating cancer as a major health problem.
Researchers found that a low-dose combination of four inhibitors is more effective in treating NSCLC with EGFR mutation. The therapy, called MLD, inhibits the action of multiple proteins in the same signaling pathway, blocking cell proliferation and tumor growth.
Researchers found that olaparib depletes the store of immature eggs in mouse ovaries by 36%, potentially affecting a woman's fertility. Fertility preservation counselling should be considered for young female patients prior to olaparib treatment.
Researchers found that a single change in the GRP94 protein causes it to behave abnormally, leading to widespread dysfunction in cells. A new small molecule PU-WS13 has been identified as a potential treatment for cancer and Alzheimer's disease by repairing defects in the defective protein.
Researchers have discovered a novel protein, death-associated protein 3 (DAP3), that drives the growth of cancers by altering genetic code. DAP3 inhibits RNA editing, which normally corrects genetic errors, acting as an oncogene and promoting cancer development.
A Yale Cancer Center study confirms the effectiveness of combining chemotherapy and trastuzumab in treating aggressive uterine serous carcinoma, a rare form of endometrial cancer. The treatment significantly improves progression-free survival, with no increase in toxicity.
A new study suggests that a type of MRI scan used for heart disease can also pick out aggressive cancers in children. The T1-mapping technique measures how water molecules interact inside cells, allowing clinicians to understand the cellular make-up of tissue and spot early signs of treatment effectiveness.
Russian scientists have discovered four new steroid substances extracted from starfish that target human breast cancer and colorectal carcinoma cells. These non-typical derivatives of polar steroids may also help nerve cells survive distress, suggesting potential applications in Alzheimer's disease prevention.
A new study has identified a key signaling pathway in the development of Paget's disease, a rare and debilitating skin cancer. Researchers found that using a topical cream containing an FDA-approved drug can alleviate clinical symptoms in patients with Paget's disease.
A new study reveals that the enzyme SAMHD1 protects B-ALL cells from nelarabine's anti-cancer effects, but not T-ALL cells. This discovery has crucial implications for leukaemia treatment, offering a potential biomarker to tailor therapy to individual patient needs.
A new study from Memorial Sloan Kettering Cancer Center finds that increased activity of the normal metabolic enzyme SHMT2 transforms normal B cells into B cell lymphomas. The enzyme binds to tumor suppressor proteins, turning them off and resulting in the development of lymphoma.
A new study finds that chemicals can cause changes in cells to evade the immune system and build resistance to cancer drugs. The team identified specific combinations of mutations that create cancer cells, which could aid doctors in prescribing the most appropriate course of chemotherapy.
Researchers at Goethe University Frankfurt and University of Kent have discovered that the enzyme SAMHD1 can split phosphate groups off nelarabine, making it less effective in B-ALL patients. This breakthrough could lead to more targeted treatment options for individual patients.
A new study finds that high deductible health plans are widening the racial health gap among black and white cancer survivors. Black cancer survivors on these plans face significant cost-related barriers to care, including skipping medication or delaying refills.
A study by Queen Mary University of London uncovers novel pathways controlling cancer progression, identifying Rac1 as a critical player in MET-driven processes. The findings may pave the way for more efficacious treatment regimens by targeting MET, PI3K, and mTOR.